Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. entered two privately negotiated exchange agreements with Streeterville Capital to swap Series Q Perpetual Preferred Stock for common shares and further adjourned its 2026 Annual Meeting of Stockholders.
On May 26, 2026 the company issued 31,958 common shares in exchange for 3.72 Series Q preferred shares, which were then cancelled. On June 1, 2026 it issued 32,710 common shares in exchange for 4.2 additional Series Q preferred shares, which were also cancelled. These exchanges were completed under Section 3(a)(9) of the Securities Act.
The 2026 Annual Meeting, previously adjourned, was further adjourned to June 8, 2026 at 8:30 a.m. Pacific Time at Jaguar Health’s San Francisco offices, with the record date remaining April 15, 2026. Stockholders who have already voted and do not wish to change their vote do not need to take any action.
Jaguar Health, Inc. has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company on May 26, 2026, and its shares continue to trade on Nasdaq, although a Nasdaq Hearings Panel will retain jurisdiction over the listing until September 1, 2026.
The company is now subject to a one-year Mandatory Panel Monitor period through May 26, 2027. If during this time the closing bid falls below $1.00 per share for 30 consecutive business days, Nasdaq would issue a delist determination without granting the usual 180‑day grace period, though Jaguar could request a new hearing.
In the accompanying press release, Jaguar highlighted that net revenue in Q1 2026 increased 816% versus Q1 2025 and 527% versus Q4 2025, driven by a U.S. out‑license agreement for Mytesi and Canalevia‑CA1 with Future Pak. The company also reiterated its focus on a pivotal‑stage development program for crofelemer in rare intestinal failure indications, targeting a new drug application around mid‑2027 and seeking a development and commercialization partner.
Jaguar Health, Inc. entered into two privately negotiated exchange agreements with Streeterville Capital, LLC, issuing 54,222 shares of common stock in exchange for 7.96 shares of Series Q Perpetual Preferred Stock, which were cancelled and retired. This follows an earlier sale of 408 Series Q preferred shares to Streeterville in prior exchange transactions.
The company also convened its 2026 Annual Meeting of Stockholders and then adjourned it to June 2, 2026 after discussions with Nasdaq, so it can provide additional information on certain proxy proposals via a forthcoming supplement. The record date for the meeting remains April 15, 2026.
Jaguar Health reported a sharp turnaround in its first quarter 2026 results, largely due to a major license deal for U.S. commercial rights to Mytesi and Canalevia-CA1. Total net revenue rose to $20,272 thousand in Q1 2026 from $2,214 thousand in Q1 2025, an 816% increase, as license and grant revenue jumped to $19,068 thousand.
Product revenue declined to $1,204 thousand from $2,171 thousand, down 45%. Income from operations moved to a profit of $10,182 thousand compared with a loss of $9,421 thousand, while net loss attributable to common stockholders narrowed to $7,015 thousand from $10,464 thousand. Non-GAAP EBITDA improved to a loss of $5,688 thousand from a loss of $9,739 thousand, and non-GAAP Recurring EBITDA improved to a loss of $5,060 thousand.
The company highlighted ongoing development of crofelemer for rare intestinal failure disorders and announced upcoming crofelemer presentations at the ESPGHAN meeting in June 2026. Jaguar also plans an investor webcast on May 26, 2026, and a management presentation at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
Jaguar Health reported a sharp turnaround in its first quarter 2026 results, largely due to a major license deal for U.S. commercial rights to Mytesi and Canalevia-CA1. Total net revenue rose to $20,272 thousand in Q1 2026 from $2,214 thousand in Q1 2025, an 816% increase, as license and grant revenue jumped to $19,068 thousand.
Product revenue declined to $1,204 thousand from $2,171 thousand, down 45%. Income from operations moved to a profit of $10,182 thousand compared with a loss of $9,421 thousand, while net loss attributable to common stockholders narrowed to $7,015 thousand from $10,464 thousand. Non-GAAP EBITDA improved to a loss of $5,688 thousand from a loss of $9,739 thousand, and non-GAAP Recurring EBITDA improved to a loss of $5,060 thousand.
The company highlighted ongoing development of crofelemer for rare intestinal failure disorders and announced upcoming crofelemer presentations at the ESPGHAN meeting in June 2026. Jaguar also plans an investor webcast on May 26, 2026, and a management presentation at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
Jaguar Health reported a sharp turnaround for the quarter ended March 31, 2026, driven by a major licensing transaction. Total revenue rose to $20.3 million from $2.2 million a year earlier, mainly from $19.0 million of license revenue under a new Mytesi and Canalevia license and supply agreement with Woodward, while product revenue declined.
The company posted net income of $8.7 million versus a $10.6 million loss in 2025, but common shareholders still saw a net loss of $7.0 million after $9.5 million of Series O preferred stock dividends and over $6.0 million of deemed preferred dividends. Cash was $7.3 million with $2.8 million in restricted cash, against total notes payable of about $33.2 million and a stockholders’ deficit of $15.8 million. Management disclosed recurring losses, a $391.1 million accumulated deficit and stated that these conditions raise substantial doubt about Jaguar’s ability to continue as a going concern over the next 12 months, even after receiving a $16.0 million upfront payment from a separate license and supply agreement.
Jaguar Health reported a sharp turnaround for the quarter ended March 31, 2026, driven by a major licensing transaction. Total revenue rose to $20.3 million from $2.2 million a year earlier, mainly from $19.0 million of license revenue under a new Mytesi and Canalevia license and supply agreement with Woodward, while product revenue declined.
The company posted net income of $8.7 million versus a $10.6 million loss in 2025, but common shareholders still saw a net loss of $7.0 million after $9.5 million of Series O preferred stock dividends and over $6.0 million of deemed preferred dividends. Cash was $7.3 million with $2.8 million in restricted cash, against total notes payable of about $33.2 million and a stockholders’ deficit of $15.8 million. Management disclosed recurring losses, a $391.1 million accumulated deficit and stated that these conditions raise substantial doubt about Jaguar’s ability to continue as a going concern over the next 12 months, even after receiving a $16.0 million upfront payment from a separate license and supply agreement.
Jaguar Health has restructured parts of two royalty financings by issuing a new class of Series Q Perpetual Preferred Stock. On May 19, 2026 it issued 500 Series Q shares to Uptown Capital in exchange for a $12,500,000 reduction in the December 2020 royalty balance and 408 Series Q shares to Streeterville Capital in exchange for a combined $10,200,000 reduction in the August 2022 royalty balance.
The Series Q Preferred Stock has a $25,000 stated value per share, no cash dividends, and accrues a 10% annual return payable in additional Series Q shares. It carries voting rights on an as-converted basis, subject to a 9.99% voting cap and a separate 9.99% beneficial ownership cap. The company may exchange Series Q into common stock at the Minimum Price, subject to trading, Nasdaq and ownership constraints, and holders have priority in liquidation up to their stated value plus accrued return.
The Certificate of Designation also imposes extensive covenants limiting new equity raises above $15,000,000, new debt repayment to these holders, capital structure changes, asset sales, reverse splits and fundamental transactions without consent of required holders, and provides default remedies including forced redemption into common stock within exchange and ownership caps.
Jaguar Health, Inc. notified the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 due to delays in obtaining and compiling required information, including material subsequent-event transactions. The company states it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
The notification indicates all other periodic reports for the prior 12 months have been filed and that the company does not anticipate a significant change in results of operations compared with the prior-year period. The form is signed by CFO Carol Lizak.
Jaguar Health, Inc. received a decision letter from a Nasdaq Hearings Panel granting a short extension to regain compliance with Nasdaq listing rules. The company recently cured a deficiency in the minimum 500,000 Publicly Held Shares requirement after third-party investors exercised existing pre-funded warrants.
The Panel reset the timeframe for Jaguar to meet the Nasdaq Bid Price Rule, requiring a closing bid price of at least $1.00 per share for 10 consecutive business days, extending the deadline from May 15, 2026 to May 18, 2026. Jaguar is working to meet these terms but notes that failure to do so would subject the company to delisting from Nasdaq.
Jaguar Health, Inc. reports an update on its Nasdaq listing compliance following a recent reverse stock split. A 1-for-35 reverse split on April 30, 2026 left the company with approximately 401,226 publicly held common shares, below Nasdaq’s 500,000 minimum for continued listing. After certain third-party investors exercised existing pre-funded warrants on May 4, 2026, Jaguar now has 513,974 common shares issued and outstanding and 513,939 publicly held shares. The company is awaiting formal Nasdaq staff confirmation that it meets the Publicly Held Shares Requirement, and it must still later demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days under Nasdaq Listing Rule 5810(c)(3)(A).
Jaguar Health, Inc. reported that Nasdaq staff notified the company it is out of compliance with the exchange’s listing rules following a recent reverse stock split. After a 1-for-35 reverse split of its common stock effective April 30, 2026, the company has approximately 401,226 publicly held shares.
This falls below Nasdaq Listing Rule 5550(a)(4), which requires at least 500,000 publicly held shares, creating an additional basis for potential delisting from The Nasdaq Capital Market. Jaguar must present its views on this new deficiency to the Nasdaq Hearings Panel in writing by May 8, 2026.
Nasdaq staff also noted the company remains out of compliance with the minimum $1.00 bid price requirement. If Jaguar cannot cure the publicly held shares deficiency and then demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, its securities may be delisted from Nasdaq.